5-amino-1MQ is a small-molecule research compound that blocks an enzyme called NNMT (nicotinamide N-methyltransferase). In mice, doing so reversed diet-induced obesity — the animals lost fat without eating less1. It is the best-known chemical tool for studying NNMT as a metabolic target, but every result to date is preclinical: there are no human trials.
In plain terms: it is not an appetite drug. It changes how fat cells handle energy, and in mice that was enough to undo obesity.
The target: NNMT
NNMT is an enzyme that is unusually abundant in the fat tissue of obese animals — so much so that body weight tracks with NNMT activity in mouse fat2. Its job is to attach a methyl group to nicotinamide, and in doing so it burns through two things a cell needs for energy metabolism: nicotinamide (a building block of NAD+, the cell's core energy-currency molecule) and SAM (S-adenosylmethionine, the body's main methyl donor)5. When NNMT runs hot in fat cells, it drains that currency; blocking it hands the currency back. In plain terms: NNMT acts like a metabolic leak in obese fat, and 5-amino-1MQ plugs it.
How it works
5-amino-1MQ — chemically, 5-amino-1-methylquinolinium — was designed as a selective, membrane-permeable NNMT inhibitor, meaning it can actually get inside cells to reach the enzyme, which earlier NNMT inhibitors struggled to do1. By inhibiting NNMT, it raises cellular NAD+ and SAM and increases energy expenditure in fat, nudging the cell toward burning rather than storing5.
What the animal studies found
The headline result comes from the compound's founding study: in diet-induced obese mice, membrane-permeable NNMT inhibitors including 5-amino-1MQ reversed high-fat-diet obesity, reducing body weight and fat mass1. A follow-up showed the effect stacks with diet — combining an NNMT inhibitor with a switch to a leaner diet accelerated fat loss, cut liver and white-fat mass, and improved fatty liver, normalising body composition toward that of lean controls6. More recent work continues to report that NNMT inhibition mitigates obesity-related metabolic dysfunction7, and the target has attracted independent drug-discovery programs beyond the original tool compound34.
| Study | Model | Key result | Year |
|---|---|---|---|
| Neelakantan1 | Obese mice | Membrane-permeable NNMT inhibitors (incl. 5-amino-1MQ) reverse high-fat-diet obesity | 2018 |
| Rudolphi2 | Mouse fat | Body weight predicts NNMT activity — links the enzyme to obesity | 2018 |
| Kannt3 | Preclinical | Independent NNMT inhibitor improves metabolic disorders | 2018 |
| Sampson6 | Obese mice | NNMT inhibitor + lean diet normalises body composition, improves fatty liver | 2021 |
| Babula7 | Preclinical | NNMT inhibition mitigates obesity-related metabolic dysfunction | 2024 |
Why it's interesting — and the catch
NNMT inhibition is appealing because it targets fat-cell *metabolism* rather than appetite, and it sits next to NAD+ biology, one of the busiest areas in metabolic and longevity research5. That NAD+ link is much of the draw: NAD+ levels fall with age, and a large slice of longevity science is a search for ways to preserve them — so an enzyme that quietly burns through NAD+ precursors in fat is an obvious thing to switch off, and 5-amino-1MQ was the tool that first showed doing so could shift whole-body metabolism1. Whether any of that translates to human ageing or metabolic health is entirely unknown; it has not been tested. The honest limits are large:
- No human data. Every study is in mice or cells. There are no clinical trials of 5-amino-1MQ, no human safety data, and no approved use.
- It is a research tool, not a drug. 5-amino-1MQ is used to *validate the target* in the lab; multiple groups are now designing newer NNMT inhibitors intended for eventual clinical translation34. NNMT also has roles in cancer and other tissues, so inhibiting it body-wide is not obviously consequence-free5.
The bottom line
5-amino-1MQ is the reference compound for a genuinely interesting metabolic target: block NNMT, spare the cell's energy currency, and — in mice — reverse obesity without cutting food intake1. As a preclinical research compound with no human evidence, though, the distance between that mouse result and a real medicine remains unbridged. This is an educational overview, not medical advice.